Write short note dwtailed on diabetic nephropathy and make pdf
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Reading File
Running Command
mkdir -p /home/daytona/workspace/diabetic-nephropathy && python3 << 'EOF' from r…
The PDF has been generated. Here is the complete detailed short note:
Diabetic Nephropathy - Detailed Short Note
1. Definition and Overview
Diabetic nephropathy (DN), also called diabetic kidney disease (DKD), is a microvascular complication of both type 1 and type 2 diabetes mellitus. It is characterised by progressive proteinuria, declining GFR, and eventual end-stage kidney disease (ESKD). It is the single leading cause of ESKD, accounting for ~50% of all patients on renal replacement therapy in the USA. Around 20-40% of diabetic patients develop nephropathy.
2. Pathogenesis
Haemodynamic: Hyperglycaemia preferentially dilates the afferent arteriole, causing glomerular hyperfiltration (GFR elevated up to 50%) and raised intraglomerular capillary pressure - the key driver of progressive injury.
Metabolic/Molecular:
- AGE formation - cross-links basement membrane proteins
- PKC activation - upregulates TGF-beta, VEGF, endothelin
- Polyol pathway activation - oxidative stress
- TGF-beta: master mediator of mesangial expansion and fibrosis
- Epigenetic "metabolic memory" perpetuates injury even after glucose normalisation
Genetic: ACE gene DD polymorphism, IL-6, IL-10, ICAM-1 variants confer susceptibility. Family history strongly predicts risk.
3. Pathological Lesions (Robbins Basic Pathology)
Glomerular:
| Lesion | Features |
|---|---|
| GBM Thickening | Earliest change; detectable by EM years before clinical disease |
| Diffuse Mesangial Sclerosis | Mesangial matrix increase + cell proliferation; leads to nephrotic syndrome |
| Kimmelstiel-Wilson Nodules | Ball-like laminated deposits in glomerular periphery; seen in 15-30%; virtually pathognomonic of diabetes |
Vascular: Hyaline arteriolosclerosis affects both afferent AND efferent arterioles - efferent involvement is virtually unique to DM.
Tubular/Interstitial: Tubulointerstitial fibrosis - correlates most closely with GFR decline; necrotising papillitis more common in DM.
4. Clinical Stages (Goldman-Cecil Medicine)
| Stage | GFR | Albuminuria | Key Features |
|---|---|---|---|
| I - Hyperfiltration | Elevated (+50%) | Nil or transient microalbuminuria | Glomerular hypertrophy; reversible |
| II - Silent | Normal/elevated | Fixed microalbuminuria (30-300 mg/24h) | BM thickening; mesangial expansion on biopsy |
| III - Overt | Declining | Macroalbuminuria >300 mg/24h; dipstick+ | Overt proteinuria; BP rising |
| IV - Advanced/ESRD | Markedly reduced | Nephrotic-range >3.5 g/24h | Uremia; uncontrolled HTN; CVD very high |
5. Diagnosis and Screening
- T1DM: Screen 5 years after diagnosis, then annually
- T2DM: Screen at diagnosis, then annually
- Test: UACR (spot urine) + eGFR
- Confirm elevated UACR on 2-3 occasions over 3-6 months
- Clinical diagnosis requires: proteinuria + retinopathy (90-95% T1DM, 60-65% T2DM) + exclusion of other causes
6. Management
Glycaemic Control: HbA1c ≤7.0%. Drug adjustments: sulfonylureas CI at eGFR <45; metformin CI at eGFR <30.
BP Control: Target <130/80 mmHg. ACEi or ARB are first-line (reduce intraglomerular pressure + proteinuria). Never combine ACEi + ARB.
Novel Nephroprotective Agents:
- SGLT2 inhibitors (empagliflozin, dapagliflozin): CREDENCE, DAPA-CKD, EMPA-KIDNEY trials - slow GFR decline, reduce ESKD
- GLP-1 receptor agonists (semaglutide): reduce albuminuria, cardiovascular mortality
- Finerenone (nonsteroidal MRA): FIDELIO-DKD - anti-fibrotic, reduces CKD progression with lower hyperkalaemia risk than spironolactone
Lifestyle: Protein 0.8 g/kg/day, sodium <2.3 g/day, smoking cessation, weight loss.
Download the PDF
Diabetic Nephropathy
PDF Document · PDF
The PDF is a fully formatted, professionally styled document (A4, colour-coded tables, section headers) covering all 8 sections: Definition, Pathogenesis, Pathology, Clinical Stages, Diagnosis & Screening, Management, ESKD/RRT, and a Key Clinical Points Summary table - sourced from Robbins Basic Pathology, Harrison's 22E, Goldman-Cecil Medicine, and Brenner & Rector's The Kidney.
This is a shared conversation. Sign in to Orris to start your own chat.